Prompted by these observations, and preclinical studies which have suggested that sclerostin antibodies can increase bone mass and bone strength in several mouse models of OI (52), sestrusumab (BPS-804) a monoclonal antibody which neutralizes sclerostin is now being investigated in the treatment of adults with OI. The gene discussed is SOST; the disease is osteogenesis imperfecta.